> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Panel Review of GSK Trelegy Ellipta sNDA Postponed
- URL: https://www.fdaweb.com/panel-review-of-gsk-trelegy-ellipta-snda-postponed/
- Published: 2020-04-07T12:00:00.000Z
- Updated: 2026-09-14T16:10:13.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5146509

*Federal Register* notice: Due to the current Covid-19 health emergency, FDA has postponed a 4/21-planned Pulmonary-Allergy Drugs Advisory Committee meeting. Panel members were scheduled to discuss a GlaxoSmithKline supplemental NDA for Trelegy Ellipta, a fixed-dose combination (fluticasone furoate, umeclidinium, and vilanterol) inhalation for reducing all-cause mortality in patients with chronic obstructive pulmonary disease (COPD). The panel was to discuss efficacy data submitted to support the proposed labeling claim, including the results from the Informing the Pathway of COPD Treatment (IMPACT) trial and the influence of inhaled corticosteroids withdrawal on the results. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2020-04-07/pdf/2020-07262.pdf?ref=fdaweb.com).